Cellosaurus PER.C6 TetR (CVCL_A7ME)
| Cell line name | PER.C6 TetR |
|---|---|
| Accession | CVCL_A7ME |
| Resource Identification Initiative | To cite this cell line use: PER.C6 TetR (RRID:CVCL_A7ME) |
| Comments | Group: Vaccine production cell line. From: Johnson & Johnson Janssen; Beerse; Belgium. Biotechnology: Used for the production of the Janssen SARS-CoV-2 (COVID-19) vaccine (Trade name: Ad26.COV2.S) (DrugBank=DB15857). In the context of the vaccine production, the tetR repressor blocks the expression of the SARS-CoV-2 spike protein gene during production of the recombinant adenoviral vector, thereby optimising vector production. Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P04483; Escherichia coli Tn10 tetR. Transformant: NCBI_TaxID; 28285; Adenovirus 5 (Note=E1). Derived from site: In situ; Fetal eye, retina; UBERON=UBERON_0003072. Cell type: Retinoblast; CL=CL_4023129. |
| Species of origin | Homo sapiens (Human) (NCBI Taxonomy: 9606) |
| Hierarchy | Parent: CVCL_G704 (PER.C6) |
| Sex of cell | Sex unspecified |
| Age at sampling | 18FW |
| Category | Transformed cell line |
| Web pages | https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf |
| Cross-references | |
| Encyclopedic resources | Wikidata; Q107116656 |
| Entry history | |
| Entry creation | 20-May-2021 |
| Last entry update | 10-Sep-2024 |
| Version number | 9 |